
A breast cancer drug that could extend the lives of hundreds of women is being withheld from the NHS in an escalation of a pricing row with the pharmaceutical industry ⬇️ thetimes.com/uk/healthcare/a…

Mum, wife, exercise fan, #MBC #BusyLivingWithMets Living with secondary breast cancer but fighting the system #enhertuemergency

A breast cancer drug that could extend the lives of hundreds of women is being withheld from the NHS in an escalation of a pricing row with the pharmaceutical industry ⬇️ thetimes.com/uk/healthcare/a…

Busy Living with Mets or on our knees waiting for the next treatment line... The public view of Metastatic Breast Cancer is more important than many realise - especially when it comes to campaigning for access to treatment, better interventions, and even practical matters like benefits and support. MBC patients are treading a fine line: needing to be “well enough” to be worth funding for extended survival, while also being “ill enough” to justify that spend. But MBC isn’t linear. One day we’re active, the next we’re in bed. One chemo can wipe out days; another allows someone to work through. Many of you will have heard us talk about the ‘severity modifier’ - especially during our campaign for Enhertu for HER2low. Because MBC doesn’t meet the current ‘high severity’ criteria, treatments can be denied. Too well, and we don’t qualify. Too unwell, and we’re deemed not worth it. A catch-22. Patients are still contributing to society, parenting, working, campaigning. Yet the median life expectancy is just 2–3 years. That sounds pretty ‘severe’ to us. #busylivingwithmets #stage4needsmore #metupuk #drugaccess #metastaticbreastcancer #secondarybreastcancer #patientvoice

📢 Amazing news! NICE has recommended capivasertib with fulvestrant for use on the NHS in England – offering certain people with HR-positive secondary breast cancer a new targeted treatment option. breastcancernow.org/about-us…

METUPUK is delighted that the drug combination capivasertib plus fulvestrant has been recommended by NICE for patients with oestrogen receptor positive metastatic breast cancer who: · have progressed on hormonal treatment · have one or more PIK3CA, AKT1 or PTEN gene alterations Capivasertib with fulvestrant is a promising drug combination which can double the length of time patients have before cancer comes back. Capivasertib is also the first drug available to inhibit AKT, a molecule which drives cancer cell growth. The Institute of Cancer Research in London had a pivotal role in the development of capivasertib. This began with unravelling the role that AKT has in cancer biology, and then working with a UK bioscience company to develop prototype drugs which could inhibit AKT. These drugs were then refined leading to the creation of the final drug capivasertib which has now been made available to patients. The process took around 25 years, beginning in the year 2000. It is always encouraging to see cancer research leading to drugs which are available to patients. However, capivasertib with fulvestrant is not a cure for metastatic breast cancer. Until the statistic of 31 women dying every day in the UK from metastatic breast cancer is no more, we at METUPUK will carry on advocating for patients. We urge the SMC to evaluate capivasertib with fulvestrant without delay. In Scotland there are no drugs available which target PIK3CA, AKT1 or PTEN gene alterations. Postcode lotteries are divisive and distressing for patients. Improved drug access allows us to stay #busylivingwithmets and increase our survival outcomes. We Demand Change. #drugapproval #darkerpink #busylivingwithmets #iamthe31 #dyingforacure #metastaticbreastcancer #severitymodifier #secondarybreastcancer #stage4needsmore #stageivneedsmore #advancedbreastcancer

The SHOCKING Truth about Turmeric and Breast Cancer youtu.be/LqYG_sArBb4?si=28sr… via @YouTube

“Your mummy loves you forever fund” 🩷 This is beautiful Hannah, my fellow Enhertu campaigner and an amazing woman, who has Stage 4 incurable cancer. Her dying wish is that her 4 year old daughter Lilah, who has complex needs, can be taken care of. Please support this GoFundMe by donating or sharing – every bit of help makes a difference Thank you 🩷 gofund.me/0a28f11

For Lilah 🩷 Please share and donate if you can X gofundme.com/f/hannahs-gift-…

Secondary breast cancer (SBC) can be referred to in a number of ways, which can be confusing. They all mean the same. SBC is a cancer that has spread beyond the breast to other parts of the body. Find out more & how we support those living with it: make2ndscount.co.uk

Today is Rare Disease Day. Those who know me understand Joshua has an ultra rare genetic mutation in ATP1A3. Today was a day to feel the sun on my face and take a breath. We live with uncertainty every day and this takes on a huge toll on us as a family. #rarediseaseday

Had a great time last night watching @BillBailey on the last night of his show with @GaryPratt44 Lovely tribute to the great Sean Lock ❤️

One of the things we hear most about at METUPUK is what we ‘shouldn’t be’ with Metastatic Breast Cancer. Either we are too ill, not ill enough, have hair when we shouldn’t or any other list of things that MBC apparently isn’t. A week rarely goes by without a story of missed diagnosis or repeated visits with something else being blamed or dismissed as ‘too young’. Patient Advocate Laura McGowan is many things that an MBC patient shouldn’t be and has written about them in a poem. So while much of the world turns red this Valentine’s Day , we are celebrating the beautiful (both outside and in) Laura and everything that she IS with Metastatic Breast Cancer. #valentinesday #metupuk #darkerpink #busylivingwithmets #iamthe31 #waitingroomfeet #breastcancer #breastcancercommunity #breastcancerjourney #breastcancersupport #dyingforacure #earlydetectionsaveslives #metastaticbreastcancer #secondarybreastcancer #secondarysisters #stage4needsmore #stageivneedsmore #advancedbreastcancer

On #worldcancerday we're sharing stories on Instagram to highlight some of the signs & symptoms patients felt before their secondary breast cancer diagnosis. @GenesisCare research shows 1 in 3 people do not know what secondary breast cancer is & we're on a mission to change that.

We're so glad you enjoyed taking part! Thanks for helping us raise life saving funds 💕

Thanks @kevinscrupps and @PygottandCrone for organising and supporting the @CoppaFeelPeople 100k fundraising event, @TracyMP1971 and I have enjoyed taking part and more importantly helping to raise money for a charity close to our hearts.

Yesterday, I spoke with @BBCLancashire to talk about living with a metastatic breast cancer diagnosis. My cancer cannot be cured, but it can be treated and currently I have no evidence of disease. I am feeling well so it’s business as usual!

2024 was another heartbreaking year for the loss of so many amazing women to metastatic/secondary breast cancer. My thoughts and love go to all of their families and friends. We need investment and access to the latest drugs and treatments to survive longer. I hope we see some advances in 2025.
One of the hardest parts about living with metastatic cancer, of any kind, is finding your tribe – friends or colleagues who just understand because they are living with it too. But in finding those people, you go into the friendships knowing full well your tribe might die before you. This year has been particularly hard for the MBC community. Every single death cuts so deep. As a New Year is almost with us, today we'd like to honour some of our METUPUK colleagues and friends that have been involved and/or worked with METUPUK who have died in the last year. We know this will be a painful list for some of you but it's important to not only remember them, but to also remind the world how many of us are dying from this disease. 31 women every single day. The whole of 2024 included the Enhertu for HER2 Low campaign. A drug rejected in England (and currently the case also in Wales and NI) which would have potentially been options for Kris Hallenga, who died in May, for Rachel Davies who died earlier this month and countless other women with HER2 Low MBC. A 2-3 year median life expectancy is not a statistic to rejoice, but rather a demonstration of how much more needs to be done. METUPUK exists solely to urgently get more done for MBC patients. More awareness. More drugs. More trials. More data. #stage4needsmore #secondarybreastcancer #mbc #metastaticbreastcancer #darkerpink #whoreallycares #iamthe31 #advancedbreastcancer #secondarybreastcancer Music: Bensound License code: 9KSDCAPIQ2YZYJFE